📅 Exo-101 shows promise in treating tissue regeneration and inflammatory diseases, targeting patients with few treatment options.
🔬 Derived from umbilical cord blood, this candidate is expected to enter clinical trials by 2027.
🤝 Both companies aim to advance therapies for high unmet medical needs.
Introduction:
This article discusses the collaboration between Exogenus Therapeutics and Lonza to develop a GMP-compliant manufacturing process for Exo-101, an exosome-based therapeutic candidate aimed at treating tissue regeneration and inflammatory diseases. Exo-101, derived from umbilical cord blood, demonstrates significant therapeutic potential due to its multifactorial mode of action.
- Exogenus Therapeutics and Lonza have partnered to advance Exo-101, an exosome-based therapeutic candidate.
- Exo-101 exhibits regenerative, anti-inflammatory, and immunomodulatory properties in preclinical models and is slated for clinical use by 2027.
- The candidate is primarily aimed at treating patients with limited treatment options in tissue regeneration and inflammatory diseases.
- Lonza will define the GMP-compliant manufacturing process for Exo-101, drawing on its expertise in exosome development.
- This collaboration is part of a commitment to innovate in therapeutic areas of high unmet medical need while utilizing biological waste materials.
Conclusion:
The partnership between Exogenus Therapeutics and Lonza represents a significant step forward in developing exosome-based therapeutics, with Exo-101 poised to address critical gaps in treatment for numerous patients. The focus on a GMP-compliant production process further underscores the commitment to safety and efficacy as the drug progresses toward clinical trials.
